BPC
EGRX

Banque Pictet & Cie’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Banque Pictet & Cie’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,958
Closed -$250K – 483
2015
Q1 		$250K Buy
+5,958
New +$169K 0.01% 412
2014
Q4 		– Sell
-13,209
Closed -$167K – 532
2014
Q3 		$167K Sell
13,209
-378
-3% -$4.69K ﹤0.01% 434
2014
Q2 		$195K Buy
13,587
+2,030
+18% +$23.1K ﹤0.01% 429
2014
Q1 		$147K Buy
+11,557
New +$157K ﹤0.01% 409

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Banque Pictet & Cie's EGRX Position: Q2 2015 in Review

Banque Pictet & Cie sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2015, closing a stake of 5,958 shares — an estimated $250K sold.

Banque Pictet & Cie first reported a position in EGRX in Q1 2014 and held it in 4 quarters. The position peaked at $250K in Q1 2015. 120 funds tracked by Wall St. Rank hold EGRX as of Q2 2015.

  • Banque Pictet & Cie reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • Banque Pictet & Cie sold 5,958 Eagle Pharmaceuticals, Inc. shares in Q2 2015, an estimated $250K.
  • Banque Pictet & Cie first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
  • Banque Pictet & Cie's Eagle Pharmaceuticals, Inc. position peaked at $250K in Q1 2015.
  • 120 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2015.

Based on Banque Pictet & Cie's 13F filing for Q2 2015, filed 7 Aug 2015.